Table 2.

Univariate analysis for OS of CML-BC.

Variable	All, n = 99							TKI treated, n = 59
	Univariate				Adjusted			Univariate				Adjusted
	n	HR	95% CI	P	HR	95% CI	P	n	HR	95% CI	P	HR	95% CI	P
Clinical factors
Age at BC (>60 y)	27	1.26	0.76–2.10	0.36	1.89	1.08–3.31	2.5 × 10−2*	19	1.34	0.68–2.63	0.40	1.35	0.68–2.67	0.39
Sex (male)	59	0.98	0.62–1.55	0.92	1.01	0.63–1.62	0.97	37	0.85	0.44–1.63	0.62	0.87	0.45–1.68	0.68
WBC (>50,000 × 103/uL)	50	0.77	0.49–1.23	0.27	0.73	0.46–1.17	0.19	27	0.50	0.26–0.96	3.6 × 10−2*	—	—	—
Hb (<9.3 g/dL)	49	1.19	0.75–1.87	0.46	0.79	0.49–1.27	0.32	25	1.20	0.63–2.27	0.58	1.07	0.55–2.08	0.85
Plt (<96,000 × 103/uL)	49	0.92	0.58–1.44	0.70	1.38	0.83–2.27	0.21	30	1.16	0.61–2.22	0.64	1.20	0.60–2.41	0.61
Lineage of blasts (myeloid)	64	2.59	1.53–4.39	3.8 × 10−4***	—	—	—	33	2.08	1.06–4.07	3.3 × 10−2*	—	—	—
Prior history of TKI before BC	36	0.93	0.58–1.51	0.78	1.05	0.64–1.73	0.84	26	1.41	0.74–2.70	0.29	0.70	0.32–1.56	0.39
TKI-based therapy for BC	59	0.36	0.23–0.58	2.0 × 10−5***	—	—	—	59	—	—	—	—	—	—
Mutations
ABL1	13	1.11	0.58–2.11	0.75	1.17	0.62–2.23	0.63	8	1.55	0.67–3.55	0.30	1.09	0.46–2.59	0.85
ASXL1	23	2.09	1.26–3.47	4.4 × 10−3**	1.30	0.76–2.25	0.34	11	2.31	1.08–4.91	3.0 × 10−2*	2.61	1.07–6.37	3.4 × 10−2*
BCOR	5	1.58	0.63–3.96	0.33	1.75	0.69–4.42	0.24	4	2.99	1.03–8.70	4.4 × 10−2*	2.57	0.84–7.85	9.7 × 10−2
BCORL1	5	1.41	0.57–3.49	0.46	1.34	0.53–3.41	0.54	3	1.44	0.44–4.72	0.55	0.90	0.27–3.07	0.87
CDKN2A/B	7	0.95	0.41–2.19	0.91	1.84	0.70–4.87	0.22	5	1.97	0.75–5.17	0.17	2.82	0.87–9.13	8.4 × 10−2
IKZF1	12	0.61	0.27–1.41	0.25	1.03	0.42–2.53	0.95	10	1.09	0.42–2.81	0.86	1.87	0.65–5.35	0.24
RUNX1	28	1.02	0.63–1.67	0.93	1.06	0.64–1.76	0.81	21	1.45	0.76–2.77	0.26	1.68	0.86–3.27	0.13
TP53	8	1.62	0.74–3.53	0.23	1.46	0.66–3.22	0.35	3	0.90	0.22–3.75	0.88	0.80	0.19–3.36	0.76
CNAs
+Ph	26	1.44	0.87–2.36	0.16	1.28	0.78–2.12	0.33	14	1.71	0.84–3.46	0.14	1.46	0.72–2.97	0.29
Complex CNAs	28	1.65	1.02–2.67	4.3 × 10−2*	1.66	1.00–2.73	4.8 × 10−2*	16	2.99	1.55–5.78	1.1 × 10−3**	3.37	1.69–6.69	5.3 × 10−4***
Hyperdiploidy	6	4.38	1.84–10.5	8.7 × 10−4***	2.28	0.93–5.57	7.0 × 10−2	1	10.99	1.28–94.1	2.9 × 10−2*	5.90	0.67–51.7	0.11
+6	6	0.91	0.33–2.52	0.86	0.75	0.27–2.08	0.58	2	0.63	0.08–4.65	0.65	0.21	0.03–1.68	0.14
−7/del(7p)	13	0.89	0.46–1.74	0.74	2.41	1.06–5.45	3.5 × 10−2*	9	0.84	0.35–2.01	0.69	1.63	0.56–4.72	0.37
+8	18	1.29	0.72–2.32	0.39	0.91	0.50–1.65	0.76	8	1.08	0.42–2.80	0.88	0.46	0.16–1.32	0.15
−9/del(9p)	9	0.87	0.40–1.89	0.72	1.30	0.52–3.25	0.57	5	1.97	0.75–5.17	0.17	2.82	0.87–9.13	8.4 × 10−2
del(17p)	13	2.78	1.50–5.18	1.2 × 10−3**	1.78	0.94–3.38	7.6 × 10−2	5	4.54	1.63–12.6	3.8 × 10−3**	2.86	0.97–8.44	5.6 × 10−2
amp(17q)	7	1.98	0.90–4.34	8.8 × 10−2	2.44	1.10–5.45	2.9 × 10−2*	5	2.59	1.00–6.73	5.0 × 10−2	2.62	0.98–6.99	5.5 × 10−2
i(17q)	4	2.81	1.00–7.84	4.9 × 10−2*	2.79	0.98–7.91	5.4 × 10−2	3	5.50	1.58–19.2	7.5 × 10−3**	2.89	0.78–10.7	0.11
+19	13	2.85	1.54–5.27	8.4 × 10−4***	1.66	0.87–3.18	0.12	4	4.48	1.49–13.5	7.5 × 10−3**	3.09	0.98–9.71	5.3 × 10−2
+21	11	2.63	1.37–5.05	3.6 × 10−3**	1.69	0.87–3.31	0.12	5	3.93	1.49–10.4	5.7 × 10−3**	3.23	1.16–8.97	2.4 × 10−2*

Univariate analysis for OS by Cox proportional hazard regression model. For all cases (n = 99), values adjusted for lineage of blasts and TKI-containing therapy for BC are also shown. For TKI treated cases (n = 59), values adjusted for WBC and lineage of blasts are also shown. Information for prior history of TKI is missing in two patients treated by TKI for BC.

95% CI 95% confidence interval, HR hazard ratio.

*P < 0.05; **P < 0.01; ***P < 0.001.